...
首页> 外文期刊>Progress in Neuro-Psychopharmacology & Biological Psychiatry: An International Research, Review and News Journal >Decreased levels of ghrelin, cortisol, and fasting blood sugar, but not n-octanoylated ghrelin, in Japanese schizophrenic inpatients treated with olanzapine.
【24h】

Decreased levels of ghrelin, cortisol, and fasting blood sugar, but not n-octanoylated ghrelin, in Japanese schizophrenic inpatients treated with olanzapine.

机译:在接受奥氮平治疗的日本精神分裂症患者中,生长素释放肽,皮质醇和空腹血糖水平降低,但正辛酰化生长素释放肽水平未降低。

获取原文
获取原文并翻译 | 示例

摘要

The mechanism by which chronic administration of olanzapine induces a marked weight gain in patients with schizophrenia remains unknown. We examined the influence of long-term treatment with olanzapine on plasma levels of hormones regulating food intake and energy homeostasis in schizophrenia. In this study, olanzapine was administered to 28 Japanese inpatients for 16 weeks after switching from typical antipsychotic drugs or risperidone. At endpoint, no significant changes in body weight or body mass index were found. There was a significant decrease in the plasma levels of ghrelin without any accompanying change in active, n-octanoylated ghrelin. Serum levels of leptin tended to be increased and a significant reduction in plasma cortisol levels was found. In addition, the levels of fasting blood sugar as well as free fatty acid were significantly decreased. Furthermore, we did not confirm any marked weight gain induced by chronic administration of olanzapine as previously reported. The reason for thisdiscrepancy may be due to differences in subjects and treatment settings. Based on these findings, it is unlikely that the decrease in plasma ghrelin levels by chronic administration of olanzapine affects weight gain. Further studies examining the effect of chronic olanzapine administration on weight and energy homeostasis in inpatients are required.
机译:长期服用奥氮平可导致精神分裂症患者体重显着增加的机制尚不清楚。我们检查了奥氮平长期治疗对精神分裂症中调节食物摄入和能量稳态的激素血浆水平的影响。在这项研究中,从28种日本抗精神病药物或利培酮转用奥氮平后,对28名日本住院患者进行了16周的治疗。终点时,体重或体重指数未见明显变化。生长素释放肽的血浆水平显着降低,而活性正辛基化生长素释放肽没有任何伴随的变化。血清瘦素水平倾向于增加,并且血浆皮质醇水平显着降低。另外,空腹血糖和游离脂肪酸的水平也显着降低。此外,如先前报道,我们并未确认长期服用奥氮平会导致体重明显增加。这种差异的原因可能是由于受试者和治疗设置的差异。基于这些发现,长期服用奥氮平引起的血浆生长素释放肽水平的降低不太可能影响体重增加。还需要进一步研究,研究长期服用奥氮平对住院患者体重和能量稳态的影响。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号